Health
Largest pharmacogenetic clinical trial in cardiology shows potential benefit in individualized approach – Mirage News
Heart patients who undergo percutaneous coronary intervention (PCI) or stent placement― nonsurgical procedures to improve blood flow to the heart ― are…
Heart patients who undergo percutaneous coronary intervention (PCI) or stent placement― nonsurgical procedures to improve blood flow to the heart ― are typically prescribed anti-platelet therapy to avoid blood clots that can lead to a heart attack or stroke. New research from the international TAILOR-PCI trial, the largest pharmacogenetics clinical trial in cardiology, suggests that genetic testing could potentially be a useful tool to help select antiplatelet medication. Pharmacogenetics is the…
-
Noosa News15 hours agoMeasles alert: Australia Zoo, Hospital ED, Sushi Hub, Holey Moley Mini Golf and train stations among QLD infection sites
-
Business15 hours ago1 ASX dividend stock down 43% I’d buy right now
-
Noosa News14 hours agoBanana farmers still salvaging fruit four weeks after ex-Tropical Cyclone Alfred
-
Noosa News14 hours agoQueen Street Mall to get a 3D digital billboard; Dutton dumps controversial plans to end flexible work; Measles alert for tourist hotspots